EXACT Sciences Corporation

$54.74
(as of Feb 4, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for EXACT Sciences Corporation

Stock Price
$54.74
Ticker Symbol
EXAS
Exchange
NASDAQ

Industry Information for EXACT Sciences Corporation

Sector
Healthcare
Industry
Diagnostics & Research

Company Description for EXACT Sciences Corporation

Website
https://www.exactsciences.com
Country
USA
Full Time Employees
6,500

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Fundamentals for EXACT Sciences Corporation

Market Capitalization
$10,132,911,104
EBITDA
$-11,337,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
2,500
Earnings per Share
$-1.16
Earnings per Share Estimate Next Year
$-0.00
Profit Margin
-7.95%
Shares Outstanding
185,076,000
Percent Owned by Insiders
1.02%
Percent Owned by Institutions
101.05%
52-Week High
$79.62
52-Week Low
$40.62

Technical Indicators for EXACT Sciences Corporation

50-Day Moving Average
$57.52
200-Day Moving Average
$56.88
RSI
45.03
ATR
2.42

Analyst Ratings for EXACT Sciences Corporation

Strong Buy
17
Buy
3
Hold
3
Sell
0
Strong Sell
0

News About EXACT Sciences Corporation

Jan 28, 2025, 9:00 AM EST
Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. See more.
Jan 21, 2025, 5:05 PM EST
Circulating tumor DNA (ctDNA) analysis and advanced tumor profiling in GI cancers highlight opportunities for recurrence monitoring and targeted therapy selection See more.
Jan 21, 2025, 5:05 PM EST
Results from prospective molecular residual disease (MRD) study show a positive Oncodetect test result is strongly associated with recurrence in stage III colon cancer patients See more.
Jan 21, 2025, 4:03 PM EST
Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test. See more.
Jan 17, 2025, 6:15 AM EST
We recently published a list of See more.